Malignant phyllodes tumor in Lynch syndrome: a case report

Shayma Kazmi *, Steven Wagner, Rebecca Heintzelman and Melanie Corbman

Abstract

Background: Lynch syndrome, or hereditary nonpolyposis colorectal cancer, is an autosomal dominant genetic syndrome that predisposes individuals to multiple cancer types. The known cancers associated with Lynch syndrome include colorectal and endometrial cancers as well as cancers of the stomach, ovary, urinary tract, hepatobiliary tract, pancreas, small bowel, and brain. There are no searchable cases of malignant phyllodes of the breast associated with Lynch syndrome.

Case presentation: Our patient was a 43-year-old Caucasian woman who felt a lump in her left breast and was found to have a spindle cell neoplasm. Definitive surgery revealed a malignant phyllodes tumor. On the basis of her cancer diagnosis and family history of multiple cancers, a Myriad myRisk Hereditary Cancer® test panel of 25 genes was performed. This testing revealed that she had a heterozygous MSH6 mutation as part of the Lynch syndrome panel. Due to positive margins, the patient received adjuvant chemotherapy with doxorubicin and ifosfamide. She also had a subsequent total abdominal hysterectomy and a bilateral salpingo-oophorectomy for risk reduction. She remains in a high-risk surveillance program. Her family members have been tested, which revealed that her two brothers and daughter also carry the genetic mutation.

Conclusions: This case highlights the importance of genetic testing with rare malignancies because the full scope of phenotypic sequelae for known hereditary syndromes has not been mapped.
Fig. 1  

**a** Ultrasound image of left breast antiradial plane at 1:00 position 9 cm from the nipple demonstrates a mixed cystic and solid, irregularly shaped, hypoechoic, and heterogeneous mass with ill-defined margins and areas of posterior acoustic enhancement. Overall lesion size is 3.7 × 2.2 × 4.0 cm.  

**b** Ultrasound image of left breast antiradial plane at 12:00 position 8 cm from the nipple demonstrates a predominately solid, lobulated, hypoechoic, and heterogeneous mass with smooth margins and only minimal posterior acoustic enhancement. Overall lesion size is 3.4 × 1.8 × 2.7 cm.  

**c** Ultrasound image of left breast split screen antiradial (left) and radial (right) planes in 2:00 position 6 cm from the nipple demonstrates a predominately solid, lobulated, homogeneous, and hypoechoic mass with smooth, well-defined margins and areas of posterior acoustic enhancement. Overall lesion size is 0.8 × 0.4 × 1.2 cm.  

**d** Ultrasound image of the left breast with panoramic view shows the lesions shown in **a** and **b** may coalesce into a single larger lesion. This coalescent lesion is congruent with the pathologic findings of an 8.8-cm lesion.
fibroadenoma with prominent epithelial elements in uniform bland myxoid stroma; and (3) 2:00 fibroadenoma. Biopsies of the spindle cell neoplasm did not display significant cytologic atypia or mitotic activity. Differential diagnoses included mucoid hamartoma, myofibroblastoma, solitary fibrous tumor, and spindle cell lipoma. Malignant phyllodes tumor was less likely, owing to the low-grade nature of the patient’s lesions.

After a multidisciplinary evaluation, the patient underwent left breast nipple-sparing mastectomy due to multiple large lesions in that breast with immediate expander placement and eventual implant. Pathology demonstrated an 8.8-cm, white-gray, rubbery mass in the upper outer quadrant (Fig. 3) consistent with a malignant phyllodes tumor showing some areas of leaf-like proliferation (Fig. 4a) but with infiltrative borders (Fig. 4b) and sarcomatous stromal overgrowth with increased mitotic activity (Fig. 4c). The superior surgical margin was positive. Mismatch repair protein immunohistochemical staining showed intact protein expression for MLH1, MSH2, and PMS2 with partial loss of protein expression for MSH6 (Fig. 5). Molecular testing for microsatellite instability (MSI) was performed and was found to be stable.

The patient then underwent left chest wall radiation therapy from late 2015 in 25 fractions, which was complicated by an admission for cellulitis. Due to positive margins and extensive disease, adjuvant chemotherapy was administered. She had three cycles of doxorubicin and ifosfamide for 2 months in early 2016, complicated by chemotherapy-induced nausea/vomiting, thrombocytopenia, and leukopenia.

Genetic counseling was initially completed to help inform surgical decisions for her newly diagnosed breast cancer. On the basis of the size of her breast tumor, unilateral mastectomy was suggested. The patient wanted information on the risk for a contralateral breast cancer in order to decide whether she should have prophylactic
mastectomy of the contralateral breast. At the initial counseling session, the patient reported a very strong maternal family history of colon, uterine, ovarian, stomach, and brain cancers suggestive of Lynch syndrome (Fig. 6). The patient underwent Myriad myRisk Hereditary Cancer® genetic testing in 2015. This panel was chosen on the basis of her young age of diagnosis of breast cancer and multiple family members with cancer diagnoses.

Although the patient was not found to carry a mutation in any of the genes associated with an increased risk for breast cancer, she was found to have an MSH6 pathogenic mutation associated with Lynch syndrome/HNPCC. She
underwent extensive counseling regarding her diagnosis. Her family was offered cascade testing for the identified mutation. As suggested by the family history, her mother had a positive test result for the MSH6 mutation. Although her mother carries the MSH6 mutation, she was cancer-free at age 65 after having had prophylactic total abdominal hysterectomy/bilateral salpingo-oophorectomy (TAH/BSO) at age 52, and had been undergoing screening with colonoscopy and endoscopic gastroduodenoscopy (EGD) based on her family history. The patient’s two brothers and daughter were also found to carry the identified MSH6 mutation and were recommended to follow National Comprehensive Cancer Network guidelines for Lynch syndrome screening.

The patient underwent a prophylactic TAH/BSO a few months after completion of therapy in 2016, and the pathology was found to be benign. She is currently followed in a high-risk program and undergoes colonoscopy/EGD, capsule endoscopy, urine cytology, and skin examinations for screening.

**Discussion**

Phyllodes tumors account for less than 1% of all breast neoplasms [3, 4]. The vast majority of phyllodes tumors occur in women, with a median age of presentation of 42 to 45 years [5–7]. Phyllodes tumors have been associated with Li-Fraumeni syndrome, a rare autosomal dominant condition that is characterized by the development of multiple tumors [8]. No other etiologic or predisposing factors have been linked to phyllodes tumors.

This case highlights an association between the diagnosis of malignant phyllodes tumor in a young woman who was ultimately diagnosed with Lynch syndrome. Lynch syndrome is an autosomal dominant genetic disorder and significantly increases risk of cancers of the colon/rectum, uterus, ovary, stomach, small bowel, hepatobiliary system, renal pelvis, ureter, and brain, as well as the risk of sebaceous neoplasms. Rare associations with breast cancers have been reported recently. No reported cases of sarcomas or malignant phyllodes tumors were discovered in a PubMed literature search. Current screening guidelines for patients with Lynch syndrome include heightened surveillance for gastrointestinal malignancies with more frequent upper and lower endoscopies [9, 10]. Women should also undergo screening for endometrial and ovarian cancers, with optional prophylactic hysterectomy/oophorectomy after childbearing has completed or at age 40. Annual urinalysis for cytology as well as dermatological and neurological examinations are also recommended [9]. Currently, annual mammograms are advised for women over the age of 40, regardless of their genetic predisposition.

Phyllodes tumors are subcategorized histologically by the World Health Organization as benign, borderline, or malignant, according to the degree of stromal overgrowth, cellular atypia, and mitotic rate. Approximately 20% of phyllodes tumors present as a nonpalpable mass identified by screening mammography [11]. There is substantial overlap of imaging findings between benign, borderline, and malignant phyllodes tumors. Mammography may demonstrate a dense, nonspiculated, and
lobulated mass. Figure 2 demonstrates development of our patient’s left breast masses over the course of 15 months as visualized by mammography. This rapid growth of breast masses has been suggested to be a common finding in malignant phyllodes tumors [12]. Ultrasound features are variable and can include irregular or oval/rounded mass, with circumscribed or noncircumscribed margins, heterogeneous or homogeneous hypoechoic pattern, and with or without posterior acoustic enhancement. Given the overlap of imaging findings among phyllodes tumors, the majority of mammographic and ultrasound features have been unable to differentiate between benign and malignant phyllodes tumors [13, 14]. The only imaging feature shown to be associated with a statistically increased likelihood of malignancy is size ≥3 cm or greater [13]. Studies evaluating breast magnetic resonance imaging (MRI) have also determined that MRI cannot reliably differentiate between a fibroadenoma and a phyllodes tumor [15].

As in our patient’s case, ultrasound demonstrated three lesions in which the largest lesion measured up to 4.0 cm. Potentially, two of the three lesions may have coalesced into the larger lesion identified on pathologic assessment of the surgical specimen. The lack of MSI within the tumor despite a known germline mutation in MSH6 and heterogeneous expression by immunohistochemistry is not an uncommon finding. Although the MSH6 gene is a component of the DNA mismatch repair, some tumors with germline mutations in MSH6 may not show MSI-high disease. Instead, they tend to show a lower level of MSI: either MSI-low or microsatellite-stable tumors [16, 17]. A proposed explanation for this is that the major function of MSH6 is thought to be in the correction of base-base mismatches, which do not give rise to MSI [18]. The lack of MSI has also been thought to be a consequence of the partial redundancy of the function of MSH6 and MSH3 proteins [17, 19].

Although no specific changes in current screening or monitoring guidelines for patients with Lynch syndrome need to be made, it is evident that these hereditary syndromes may harbor propensity for more cancers than previously noted. We recommend genetic counseling for any patient who harbors a rare cancer, because the link to genetic syndromes is not yet definitive owing to the paucity of cases.

**Abbreviations**
EGD: Endoscopic gastroduodenoscopy; HNPCC: Hereditary nonpolyposis colorectal cancer; MLH1: Human MutL homolog 1; MRI: Magnetic resonance imaging; MSH2: MutS protein homolog 2; MSH6: MutS protein homolog 6; MSI: Microsatellite instability; p63: Transformation-related protein 63; PMS2: PMS protein homolog 2; TAH/BSO: Total abdominal hysterectomy/bilateral salpingo-oophorectomy

**Acknowledgements**
We acknowledge Jeffrey Hoag for his editorial contribution to this case report.

**Authors’ contributions**
SK wrote the majority of the case report and the abstract and submitted the manuscript for publication. SW analyzed the imaging, selected appropriate images for the case report, and edited as appropriate. RH reviewed the pathology, selected appropriate pathology slide images for the case report, and edited the “Discussion” section. MC reviewed the case report, edited the genetic testing portion, and inserted the family tree. All authors read and approved the final manuscript.

**Funding**
There was no funding for this case report.

**Availability of data and materials**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Consent for publication
See attached.

Competing interests
The authors declare that they have no competing interests.

Received: 19 March 2019 Accepted: 29 May 2019
Published online: 16 July 2019

References
1. Bonadonna V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304–10.
2. Roberts M, Jackson S, Susswein L, et al. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer. Genetic Med. 2018;20(10):1167–74.
3. Reinuss M, Mitus J, Duda K, et al. The treatment and prognosis of patients with phyllodes tumor of the breast; an analysis of 170 cases. Cancer. 1996;77:910–6.
4. Geisler DP, Boyle MJ, Malnar KE, et al. Phyllodes tumors of the breast; a review of 32 cases. Am Surg. 2000;66:360–6.
5. Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer. 1993;71:3020–4.
6. Norris HJ, Taylor H. Relationship of histologic features to behavior of cystosarcoma phyllodes: analysis of ninety-four cases. Cancer. 1967;20:2090–9.
7. Barrio AV, Clark BD, Goldberg JL, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 2007;14:2961–70.
8. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20:4621–8.
9. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome; a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum. 2014;57:1025–48.
10. Engel C, Rahner N, Schulmann K, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol. 2010;8:174–82.
11. Macdonald OK, Lee CM, Tward JD, et al. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer. 2006;107:2127–33.
12. Majeski J, Stroud J. Malignant phyllodes tumors of the breast: a study in clinical practice. Int Surg. 2012;97:95–8.
13. Liberman L, Bonaccio E, Hamele-Bena D, et al. Benign and malignant phyllodes tumors: Mammographic and sonographic findings. Radiology. 1996;189:121–4.
14. Kalambo M, Adriana B, Adeyefu M, et al. Phyllodes tumor of the breast: ultrasound-pathology correlation. Am J Roentgenol. 2018;210:W173–9.
15. Wurdinger S, Herzog AB, Fischer DR, et al. Differentiation of phyllodes breast tumors from fibroadenomas on MRI. AJR Am J Roentgenol. 2005;185:1317–21.
16. Wu Y, Berends MJW, Mensink RGJ, et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet. 1999;65:1291–8.
17. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part II the utility of microsatellite instability testing. J Mol Diagn. 2008;10(4):301–7.
18. Berends MJW, Wu Y, Simons RH, et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet. 2002;70:26–37.
19. Umar A, Risengt JI, Glaab WE, et al. Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics. 1998;148:1637–46.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.